Future studies are needed to evaluate the potential benefits of nocturnal melatonin supplementation on breast cancer risk in women taking HT and to compare the efficacy of MEPT on other breast cancer subtypes, such as ER+, PR+, and triple negative breast cancers. The gene discussed is PGR; the disease is breast carcinoma.